{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-26-029761","form_type":"8-K","ticker":"IXHL","cik":"0001873875","company_name":"Incannex Healthcare Inc.","filed_at":"2026-03-18T23:59:59+00:00","discovered_at":"2026-05-14T18:02:36.638225+00:00","generated_at":"2026-05-15T09:56:07.107363+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Incannex reports ~$75M cash, no debt; advances IHL-42X sleep apnea program","bullets":["Cash position ~$75M, no debt; market cap ~$46M, resulting in negative enterprise value.","Financing led by healthcare-focused institutional investors funds DReAMzz dose-optimization study for IHL-42X.","Company expects to start dosing DReAMzz study within months; Phase 2 results showed significant OSA improvements.","PSX-001 for generalized anxiety disorder progressing with open IND and clinical advisory board.","Board-approved share buyback program remains available for shareholder value delivery."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-26-029761","json":"https://secwatch.observer/filing/0001213900-26-029761.json","markdown":"https://secwatch.observer/filing/0001213900-26-029761.md","text":"https://secwatch.observer/filing/0001213900-26-029761.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1873875/000121390026029761/0001213900-26-029761-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1873875/000121390026029761/ea0282288-8k_incannex.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T09:56:07.107363+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}